393 related articles for article (PubMed ID: 35795687)
1. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
Millan MJ
Ther Adv Psychopharmacol; 2022; 12():20451253221105128. PubMed ID: 35795687
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
Vimala PV; Bhutada PS; Patel FR
Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
[TBL] [Abstract][Full Text] [Related]
3. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Millan MJ; Brocco M; Gobert A; Dekeyne A
Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
[TBL] [Abstract][Full Text] [Related]
4. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
De Berardis D; Fornaro M; Serroni N; Campanella D; Rapini G; Olivieri L; Srinivasan V; Iasevoli F; Tomasetti C; De Bartolomeis A; Valchera A; Perna G; Mazza M; Di Nicola M; Martinotti G; Di Giannantonio M
Int J Mol Sci; 2015 Jan; 16(1):1111-30. PubMed ID: 25569089
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine in treating generalized anxiety disorder.
Demyttenaere K
Expert Opin Investig Drugs; 2014 Jun; 23(6):857-64. PubMed ID: 24766542
[TBL] [Abstract][Full Text] [Related]
6. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder.
Levitan MN; Papelbaum M; Nardi AE
Neuropsychiatr Dis Treat; 2015; 11():1149-55. PubMed ID: 25999720
[TBL] [Abstract][Full Text] [Related]
7. Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine.
Stein DJ
Adv Ther; 2021 Sep; 38(Suppl 2):52-60. PubMed ID: 34417992
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
Stein DJ; Ahokas AA; de Bodinat C
J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine in depressive disorders: its novel mechanisms of action.
Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
[TBL] [Abstract][Full Text] [Related]
10. The interaction between the internal clock and antidepressant efficacy.
Racagni G; Riva MA; Popoli M
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
[TBL] [Abstract][Full Text] [Related]
11. Melatonergic drugs in clinical practice.
Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
[TBL] [Abstract][Full Text] [Related]
12. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.
Kamal M; Gbahou F; Guillaume JL; Daulat AM; Benleulmi-Chaachoua A; Luka M; Chen P; Kalbasi Anaraki D; Baroncini M; Mannoury la Cour C; Millan MJ; Prevot V; Delagrange P; Jockers R
J Biol Chem; 2015 May; 290(18):11537-46. PubMed ID: 25770211
[TBL] [Abstract][Full Text] [Related]
13. Agomelatine: An Astounding Sui-generis Antidepressant?
Naveed M; Li LD; Sheng G; Du ZW; Zhou YP; Nan S; Zhu MY; Zhang J; Zhou QG
Curr Mol Pharmacol; 2022; 15(7):943-961. PubMed ID: 34886787
[TBL] [Abstract][Full Text] [Related]
14. Evidence of agomelatine's antidepressant efficacy: the key points.
Eser D; Baghai TC; Möller HJ
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S15-9. PubMed ID: 17917562
[TBL] [Abstract][Full Text] [Related]
15. Studies into the anxiolytic actions of agomelatine in social isolation reared rats: Role of corticosterone and sex.
Regenass W; Möller M; Harvey BH
J Psychopharmacol; 2018 Feb; 32(2):134-145. PubMed ID: 29082818
[TBL] [Abstract][Full Text] [Related]
16. Agomelatine affects rat suprachiasmatic nucleus neurons via melatonin and serotonin receptors.
Yang J; Jin HJ; Mocaër E; Seguin L; Zhao H; Rusak B
Life Sci; 2016 Jun; 155():147-54. PubMed ID: 27269050
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
18. A review of preliminary observations on agomelatine in the treatment of anxiety disorders.
Levitan MN; Papelbaum M; Nardi AE
Exp Clin Psychopharmacol; 2012 Dec; 20(6):504-9. PubMed ID: 23088208
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
